Effects Of Madopar On Levels Of Plasma Folate, Vitamin B12 In Patients With Parkinson’s Disease Or Vascular Parkinsonism

Objective:To explore the effects of madopar on levels of plasma folate, vitamin B12 in patients with parkinson’s disease or vascular parkinsonism.Methods:Collected 50 cases of patients with Parkinson’s disease(PD group), 41 cases of patients with vascular parkinsonism(VP group), and 49 cases volunteers(control group) in the second hospital of Shanxi Medical University from January 2011 to December 2014.General detailed records of all patients clinical data(gender, age, history of hypertension,diabetes) and laboratory index results(fasting plasma folic acid,vitamin B12,homocysteine,and lipid levels),according to whether using of Madopar treatment,these patients can divided into PD(drug group, untreated group),VP(drug group, untreated group)and control group.The time that patients using Madopar are longer than 6 months.Compare of the levels of plasma folic acid,vitamin B12 and so on.Results:1.For Parkinson’s disease patients treated group, no drug group and the control group,the comparation of serum levels of FA demonstrate that, the first group is lower than thelast two and the difference was statistically significant(P<0.01),but no statistically significant difference between the latter two(P> 0.05); the comparation of serum levels of Vit B12 shows that the first group is lower than the last two,three groups compared separately,the difference was statistically significant(P<0.01);compared HCY levels,drug group is higher than the last two group,they have statistically significant(P<0.01)between each other; the comparation of plasma levels of Apo B100,the first two group is lower than the control group,the difference is statistically significant(P<0.01),the difference between the first two group had no significant difference(P>0.05); the comparation of serum levels of Lpa, they have statistically significant difference between each other(P<0.01), the first two group is higher than the last one, the former two group have no significant difference between each other(P>0.05). 2.Vascular parkinsonism patients with medication group, no treatment group, compared to the control group, about serum levels of FA, medication group is lower than the latter two, the difference was statistically significant(P<0.01), but the latter two have no statistically significance(P>0.05); the comparation of serum levels of Vit B12 the first group is lower than the last two, the difference was statistically significant(P<0.01), the latter two have no significant difference between each other(P>0.05); about serum levels of HCY,the treatment group is higher than the latter two, the difference about the three group was statistically significant(P<0.01); the comparation of serum levels of Lpa, the two group higher than the last group,the difference was statistically significant(P<0.01),but the difference between first two have not statistically significant(P>0.05).3.The Parkinson’s disease, Vascular parkinsonism groups of no drug group compared with the control group: the serum levels of FA was no significant difference compared each other(P>0.05); about the plasma levels of Vit B12,thefirst group is lower than the latter two, the difference was statistically significant(P<0.01),the latter two have no significant difference(P>0.05); the serum levels of HCY, the former two are higher than the last group,the difference was statistically significant(P<0.01), but the first two have no significant difference(P>0.05); the comparation of plasma levels of Apo B100, Parkinson’s disease without medicationgroup is lower than the later two, the difference was statistically significant(P<0.01), the latter two have no statistical significance(P>0.05); about the serum levels of Lpa, the fires two groups are higher than the last one, the difference was statistically significant(P<0.01), the difference between the former two have no statistically significant(P> 0.05).Conclusions:For the patients of parkinson’s disease and vascular parkinsonism, the using of madopar longer than 6 months can reduce folic acid,vitamin B12 levels, but elevated homocysteine levels. Low levels of Vit B12 and Apo B100, high levels of homocysteine and Lpa may be associated with Parkinson’s disease. High levels of homocysteine and Lpa may be associated with vascular parkinsonism.